Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | OGT | O15294 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11842784 | 0.68 | MAOA (0.42) | MAOAMAOBFTO | |
| SCHEMBL30752490 | 0.68 | DAO (0.46) | DAOMAOAMAOBFTOOGT | |
| SCHEMBL1498253 | 0.68 | POLB (0.30) | POLB | |
| SCHEMBL218085 | 0.66 | — | — | |
| SCHEMBL1673129 | 0.65 | NOS1 (0.37) | POLB | |
| SCHEMBL11268792 | 0.64 | MAPKAPK2 (0.41) | DAO | |
| SCHEMBL11829893 | 0.63 | MAOA (0.37) | MAOAMAOBPOLB | |
| SCHEMBL3360781 | 0.63 | DAO (0.53) | DAO | |
| SCHEMBL10417 | 0.63 | CA12 (0.48) | DAO | |
| SCHEMBL29371690 | 0.63 | CA12 (0.48) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222682913-U | High-efficiency conveying device for pyrimidofuranone powder | 江西联柏科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-221772150-U | Magnetic heating stirrer for preparing pyrimidofuranone | 江西联柏科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-219284742-U | Pyrimidine furanone synthetic sample collector | 临沂晟泰高分子材料有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-219186826-U | Pyrimidine furanone contactless adding equipment | 临沂晟泰高分子材料有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115557901-A | Efficient production method of pyrimidofuranone | 湖北有宜新材料科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-212731311-U | Layering washing device of pyrimidofuranone processing usefulness | 临沂晟泰高分子材料有限公司 | 2021-03-19 | — | — | CN | claimed |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. | 2007-09-13 | — | — | US | claimed |
| EP-1551962-A4 | MITOTIC KINESIN BINDING SITE | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1359921-A4 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS INC (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1551962-A2 | MITOTIC KINESIN BINDING SITE | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1359921-A2 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NewBiotics, Inc. (US) | 2003-11-12 | — | — | EP | claimed |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | CELMED ONCOLOGY (USA), INC. (CA) | 2002-10-17 | — | — | US | claimed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002056832-A2 | METHODS TO TREAT AUTOIMMUNE AND INFLAMMATORY CONDITIONS | NEWBIOTICS, INC. (US) | 2002-07-25 | — | — | WO | claimed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| CN-222682913-U | High-efficiency conveying device for pyrimidofuranone powder | 江西联柏科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-222682913-U | High-efficiency conveying device for pyrimidofuranone powder | 江西联柏科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147175-A1 | Synergistic ECTA compositions | ENTPD1, ENTPD2, ENPP1 | DAO 1872/4885MAOA 339/4885MAOB 1040/4885 |
| US-20020151519-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | DAO 344/4885MAOA 1737/4885MAOB 1256/4885 |
| US-20070213307-A1 | Methods to treat autoimmune and inflammatory conditions | SSB, ENPP2, TPMT | DAO 344/4885MAOA 1737/4885MAOB 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.